Govt Earmarks Rs 1 000 Cr For Promotion Of Bulk Drug Parks

New Delhi: The government has earmarked Rs 1,000 crore for the promotion of bulk drug parks for FY25, a multi-fold increase from Rs 85.15 crore outlay in the revised estimate for the ongoing fiscal.

Initially, the government had earmarked Rs 900 crore in the Budget for 2023-24. However, the revised estimate presented in the Parliament in the Interim Budget 2024-25 for ‘Promotion of Bulk Drug Parks’ was at Rs 85.15 crore.

According to the Expenditure Budget document, the total outlay for the development of the pharmaceutical industry for FY25 has been pegged at Rs 1,300 crore, up from Rs 264.67 crore in the revised estimate of FY24.

Similarly, the outlay for ‘promotion of medical device parks’ has been increased to Rs 150 crore for FY25, up from Rs 64 crore in the revised estimate for FY24.

Further, the allocation for assistance to medical device clusters for common facilities (AMD-CF) has been raised to Rs 40 crore for FY25 from Rs 33 crore in the revised estimate for FY24.

For the Jan Aushadhi scheme, the initiative to provide affordable generic medicines in the country, the outlay has been hiked to Rs 284.5 crore for FY25, up from Rs 110 crore in the revised estimate for FY24.

Related Posts

  • Pharma
  • July 26, 2024
  • 116 views
US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

Maryland: The US Food and Drug Administration (FDA) has warned Brassica Pharma for numerous good manufacturing practice (GMP) violations, including multiple instances of employees falsifying sterility and environmental monitoring data and…

  • Pharma
  • July 26, 2024
  • 108 views
Indian National Charged With Selling Counterfeit Cancer Drugs

HOUSTON: A federal grand jury has returned an indictment charging an Indian national with selling and shipping tens of thousands of dollars in counterfeit oncology pharmaceuticals into the United States,…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

US FDA Finds Data Integrity, Sterility Problems At Brassica Pharma

Indian National Charged With Selling Counterfeit Cancer Drugs

Indian National Charged With Selling Counterfeit Cancer Drugs

ICMR Releases 32 New Treatment Standards For Treating Common And Serious Diseases

ICMR Releases 32 New Treatment Standards For Treating Common And Serious Diseases

BIS Sanctioned 82 Medical Device Projects To Develop Standards

BIS Sanctioned 82 Medical Device Projects To Develop Standards

Anti-Narcotics Task Force Will Be Formed Soon In Rajasthan: HM

Anti-Narcotics Task Force Will Be Formed Soon In Rajasthan: HM

‘Sunrise’ MedTech Industry in India & ‘Clouds’ strangling it, Brainstormed in PHD

‘Sunrise’ MedTech Industry in India & ‘Clouds’ strangling it, Brainstormed in PHD